Contact this trialFirst, we need to learn more about you.
BTK Inhibitor
Pirtobrutinib + Venetoclax for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial studies how two drugs (pirtobrutinib and venetoclax) can treat Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and measure a blood test (minimal residual disease) to guide treatment length.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service